DeutschNewstral
Article
Mmarketwatch.com on 2019-11-21 14:26
ProQR shares rises on FDA orphan drug designation
Related news
SA biotech gets FDA orphan drug designationbizjournals.com- MSeres shares drop 7% after news of FDA orphan drug designation for ulcerative colitis therapymarketwatch.com
- MAkari Therapeutics shares soar 13% premarket after FDA grants Orphan Drug designation to nomacopanmarketwatch.com
Sapience Therapeutics ST-36 receives orphan drug designation from FDAwestfaironline.com- Imbrium Therapeutics receives FDA orphan drug designation for biliary tract cancer drugwestfaironline.com
- MIovance shares jump on FDA cancer drug fast-track designationmarketwatch.com
- MAcadia shares rise on FDA dementia drug designationmarketwatch.com
- MOrgenesis shares soar 19% premarket after FDA grants orphan designation to insulin techmarketwatch.com
FDA Issues Draft Guidance on Orphan Drug Designation in Pediatric Subpopulationsjdsupra.com- Philadelphia gene therapy company gets FDA Orphan Drug Designation for lead product candidatebizjournals.com
- MAlnylam Pharma stock rises 1.5% after FDA gives drug 'breakthrough therapy' designationmarketwatch.com
- MCan-Fite Bio shares surge about 40% as liver drug gets FDA fast track designationmarketwatch.com
- Durham cancer drug developer sees shares pop 35% on FDA designationbizjournals.com
- MKrystal Biotech shares up 27% after company's skin drug receives expedited review designation from FDAmarketwatch.com
Lundbeck's Carnexiv gets FDA orphan drug statusdailyherald.com- FDA pilot program could help Wave avoid orphan-drug pitfallsbizjournals.com
- FDA finalizes guidance on Orphan Drug “sameness” of gene therapiesjdsupra.com
- MBeiGene drug gets 'breakthrough therapy' designation from FDAmarketwatch.com
- MPuma Biotech stock surges on FDA cancer drug designationmarketwatch.com
Cerecor has FDA fast track designation for rare disease drugthedailyrecord.com